Summit Therapeutics Inc. (SMMT) earnings
SMMT earnings moved a median of -1.93% by the close. Quarterly and annual SMMT reports and results, each read against the price at its own news timestamp. Back to the SMMT overview →
18 measured SMMT earnings events.
Where these SMMT earnings landedvs 17 measured SMMT earnings reactions
| Middle 50% of SMMT earnings reactions | -11.19% to +1.94% |
|---|---|
| Median reaction (to close) | -1.93% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 SMMT earnings events with a measured close landed between -11.19% and +1.94%; 47% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Summit Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.15% | +0.44% | |
| Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026 | Press release | -1.03% | -7.65% | |
| Form 10-Q Summit Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | -2.31% | +0.59% | |
| Form 10-K Summit Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | +2.31% | +2.15% | |
| Form 10-Q Summit Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | +5.86% | +7.25% | |
| Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 | Press release | +2.70% | +1.94% | |
| Form 10-Q Summit Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.70% | — | |
| Form 10-Q Summit Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | +7.98% | +7.60% | |
| Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025 | Press release | -1.13% | -31.99% | |
| Form 10-K Summit Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | -11.12% | -15.89% | |
| Form 10-Q Summit Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.95% | -11.19% | |
| Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024 | Press release | +1.40% | -3.33% | |
| Form 10-Q Summit Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.39% | -7.02% | |
| Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024 | Press release | +2.66% | -1.93% | |
| Form 10-Q Summit Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.79% | +19.90% | |
| Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 | Press release | +0.85% | +0.85% | |
| Form 10-K Summit Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | -5.24% | -23.20% | |
| Form 10-Q Summit Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.46% | -11.75% |
Keep exploring
More SMMT: analyst actions → · SEC filings → · SMMT overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Veracyte, Inc. (VCYT) | 427 | -0.15% | 46% |
| Moleculin Biotech, Inc. (MBRX) | 426 | -0.21% | 43% |
| Scholar Rock Holding Corporation (SRRK) | 425 | 0.00% | 49% |
| Koninklijke Philips N.V. NY Registry Shares (PHG) | 424 | +0.04% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.